Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Jeffrey M. Miller, M.D.
Jeffrey M. Miller, M.D.

Specialty:

Hematology/Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Assistant Clinical Professor, David Geffen School of Medicine, Olive View-UCLA Medical Center, Division of Hematology/Oncology
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Olive View-UCLA Medical Center

Education:

Fellowship:
Hematology/Oncology, University of Maryland Cancer Center, 1991 - 1994
Residency:
Seton Hall University, 1988 - 1991
Medical Degree:
M.D., Ross University, 1988

Certification(s):

Medical Board Certification(s):
Internal Medicine, American Board of Internal Medicine, 1991, 2005
Hematology, 1994, 2005
Medical Oncology, 1995, 2005

Contact Information:

Phone:
(818) 364-3205
Email:

Scientific Interest(s):

Dr. Jeffrey M. Miller is interested in hematologic malignancies, general oncology, and clinical trials.

Selected Cancer-Related Publications:

Lipshutz GS, Pham PC, Ghobrial MR, Wallace WD, Miller JM, Pham PT. Thrombotic microangiopathy following pancreas after kidney transplants. Clin Transplant. 2008 Mar-Apr;22(2):236-41.

Pham PT, Pham PM, Miller JM, Pham PC. Polyclonal antibody-induced serum sickness presenting as rapidly progressive descending paralysis. Transplantation. 2007 Jun 27;83(12):1657.

Pham PT, Wilkinson AH, Gritsch HA, Pham PC, Miller JM, Lassman CR, Danovitch GM. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. Transplant Proc. 2002 Jun;34(4):1178-81.

Pham PT, Miller JM, Demetrion G, Lew SQ. Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient. Am J Kidney Dis. 1995 Apr;25(4):642-7.